647 related articles for article (PubMed ID: 7735692)
1. Cardiovascular effects of the calcium sensitizer, levosimendan, in heart failure induced by rapid pacing in the presence of aortic constriction.
Udvary E; Papp JG; Végh A
Br J Pharmacol; 1995 Feb; 114(3):656-61. PubMed ID: 7735692
[TBL] [Abstract][Full Text] [Related]
2. Levosimendan enhances left ventricular systolic and diastolic function in conscious dogs with pacing-induced cardiomyopathy.
Pagel PS; McGough MF; Hettrick DA; Lowe D; Tessmer JP; Jamali IN; Warltier DC
J Cardiovasc Pharmacol; 1997 May; 29(5):563-73. PubMed ID: 9213196
[TBL] [Abstract][Full Text] [Related]
3. Systemic and coronary hemodynamic actions and left ventricular functional effects of levosimendan in conscious dogs.
Harkin CP; Pagel PS; Tessmer JP; Warltier DC
J Cardiovasc Pharmacol; 1995 Aug; 26(2):179-88. PubMed ID: 7475041
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the effects of levosimendan, pimobendan, and milrinone on canine left ventricular-arterial coupling and mechanical efficiency.
Pagel PS; Hettrick DA; Warltier DC
Basic Res Cardiol; 1996; 91(4):296-307. PubMed ID: 8874779
[TBL] [Abstract][Full Text] [Related]
5. Levosimendan (OR-1259), a myofilament calcium sensitizer, enhances myocardial contractility but does not alter isovolumic relaxation in conscious and anesthetized dogs.
Pagel PS; Harkin CP; Hettrick DA; Warltier DC
Anesthesiology; 1994 Oct; 81(4):974-87. PubMed ID: 7943849
[TBL] [Abstract][Full Text] [Related]
6. A dose-response study of levosimendan in a porcine model of acute ischaemic heart failure.
Kolseth SM; Wahba A; Kirkeby-Garstad I; Aro S; Nordgaard H; Høydal M; Rognmo Ø; Nordhaug D
Eur J Cardiothorac Surg; 2012 Jun; 41(6):1377-83. PubMed ID: 22219475
[TBL] [Abstract][Full Text] [Related]
7. Levosimendan potentiates the inotropic actions of dopamine in conscious dogs.
McGough MF; Pagel PS; Lowe D; Hettrick DA; Warltier DC
J Cardiovasc Pharmacol; 1996 Jul; 28(1):36-47. PubMed ID: 8797134
[TBL] [Abstract][Full Text] [Related]
8. Levosimendan restores the positive force-frequency relation in heart failure.
Masutani S; Cheng HJ; Tachibana H; Little WC; Cheng CP
Am J Physiol Heart Circ Physiol; 2011 Aug; 301(2):H488-96. PubMed ID: 21572004
[TBL] [Abstract][Full Text] [Related]
9. Ca2+ sensitizer superior to catecholamine during myocardial stunning?
Meyer K; Klocke RC; Schipke JD; Gams E; Korbmacher B
Eur J Cardiothorac Surg; 2008 Aug; 34(2):326-31. PubMed ID: 18539040
[TBL] [Abstract][Full Text] [Related]
10. Direct myocardial effects of levosimendan in humans with left ventricular dysfunction: alteration of force-frequency and relaxation-frequency relationships.
Givertz MM; Andreou C; Conrad CH; Colucci WS
Circulation; 2007 Mar; 115(10):1218-24. PubMed ID: 17339544
[TBL] [Abstract][Full Text] [Related]
11. Effects of levosimendan on left ventricular function: correlation with plasma concentrations in conscious dogs.
McGough MF; Pagel PS; Lowe D; Hettrick DA; Kersten JR; Warltier DC
J Cardiothorac Vasc Anesth; 1997 Feb; 11(1):49-53. PubMed ID: 9058220
[TBL] [Abstract][Full Text] [Related]
12. The effect of levosimendan during long-term amiodarone treatment in dogs.
Papp JG; Pollesello P; Varró A; Végh A; Udvary E
Basic Clin Pharmacol Toxicol; 2006 Jul; 99(1):27-32. PubMed ID: 16867167
[TBL] [Abstract][Full Text] [Related]
13. Haemodynamic interactions of a new calcium sensitizing drug levosimendan and captopril.
Antila S; Eha J; Heinpalu M; Lehtonen L; Loogna I; Mesikepp A; Planken U; Sandell EP
Eur J Clin Pharmacol; 1996; 49(6):451-8. PubMed ID: 8706769
[TBL] [Abstract][Full Text] [Related]
14. Orally available levosimendan dose-related positive inotropic and lusitropic effect in conscious chronically instrumented normal and heart failure dogs.
Masutani S; Cheng HJ; Hyttilä-Hopponen M; Levijoki J; Heikkilä A; Vuorela A; Little WC; Cheng CP
J Pharmacol Exp Ther; 2008 Apr; 325(1):236-47. PubMed ID: 18174383
[TBL] [Abstract][Full Text] [Related]
15. Levosimendan restores both systolic and diastolic cardiac performance in lipopolysaccharide-treated rabbits: comparison with dobutamine and milrinone.
Barraud D; Faivre V; Damy T; Welschbillig S; Gayat E; Heymes C; Payen D; Shah AM; Mebazaa A
Crit Care Med; 2007 May; 35(5):1376-82. PubMed ID: 17414729
[TBL] [Abstract][Full Text] [Related]
16. Levosimendan improves cardiac function and survival in rats with angiotensin II-induced hypertensive heart failure.
Biala A; Martonen E; Kaheinen P; Levijoki J; Finckenberg P; Merasto S; Louhelainen M; Muller DN; Luft FC; Mervaala E
Hypertens Res; 2010 Oct; 33(10):1004-11. PubMed ID: 20811386
[TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamics and safety of a new calcium sensitizer, levosimendan, and its metabolites during an extended infusion in patients with severe heart failure.
Kivikko M; Antila S; Eha J; Lehtonen L; Pentikäinen PJ
J Clin Pharmacol; 2002 Jan; 42(1):43-51. PubMed ID: 11808823
[TBL] [Abstract][Full Text] [Related]
18. Levosimendan improves LV systolic and diastolic performance at rest and during exercise after heart failure.
Tachibana H; Cheng HJ; Ukai T; Igawa A; Zhang ZS; Little WC; Cheng CP
Am J Physiol Heart Circ Physiol; 2005 Feb; 288(2):H914-22. PubMed ID: 15486041
[TBL] [Abstract][Full Text] [Related]
19. Effect of levosimendan on balance between ATP production and consumption in isolated perfused guinea-pig heart before ischemia or after reperfusion.
Eriksson O; Pollesello P; Haikala H
J Cardiovasc Pharmacol; 2004 Sep; 44(3):316-21. PubMed ID: 15475828
[TBL] [Abstract][Full Text] [Related]
20. Zatebradine, a specific bradycardic agent, alters the hemodynamic and left ventricular mechanical actions of levosimendan, a new myofilament calcium sensitizer, in conscious dogs.
Pagel PS; Harkin CP; Hettrick DA; Warltier DC
J Pharmacol Exp Ther; 1995 Oct; 275(1):127-35. PubMed ID: 7562540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
